|
Partner 20: University of Copenhagen[UCPH], Copenhagen, Denmark Scientist responsible: Prof. S. Moein Moghimi
The development of a wide spectrum of promising nanoscale materials, either in their own right or as a component of multifunctional platforms, is beginning to have a paradigm-shifting impact in medicine; they are changing the foundations of disease diagnosis, monitoring and treatment, and turning molecular discoveries into benefits for patients. Research into delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents via intravenous and interstitial routes of administration with particulate drug carriers and nanoconstructs is at the forefront of projects in nanomedicine, but the biological performance of such delivery systems still requires optimization. However, the future of particulate and polymeric nanomedicines will depend on rational design of nanotechnology materials and tools based around a detailed and thorough molecular understanding of biological processes, rather than forcing applications for some materials currently in vogue. Therefore, the prime research focus of the Centre is to unravel the molecular basis of nanomaterial performance and toxicity through “structure-activity” assessments at membrane, organelle, cellular and animal level in combination with and by improving/optimizing the performance of the state-of-the-art bio-nanotechnology techniques. This integrated and multidisciplinary approach is expected to improve therapeutic benefit-to-risk ratio. CPNN also intend to provide “bench-mark protocols” for toxicity evaluation of nanomedicines in animals, and at cellular and molecular levels, as the sensitivity and precision of the standard toxicological procedures are of arguable value in nanomedicine research and development as it is limited to spotting extreme toxicity.
Keywords: Drug delivery systems; Gene and nucleic acid transfer; Immunobiology; Immunological reactions; Liposomes; Nanomedicine; Nanoparticulate systems; Nanoparticle tracking; Nanoplatforms; Molecular toxicology; Polymeric constructs
Contact Details:
SM MOGHIMI Professor of Nanomedicine Department of Pharmaceutics and Analytical Chemistry (Faculty of Pharmaceutical Sciences) and The NanoScience Center Director, Centre for Pharmaceutical Nanotechnology and Nanotoxicology University of Copenhagen Universitetsparken 2 DK-2100 Copenhagen Ø Denmark
e.mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Representative publications:
1. Moghimi, S. M.* and Andresen, T. L. (2009) Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicine. Mol. Immunol. 46: 1571–1572. 2. Hamad, I., Hunter, A. C., Rutt, K. J., Liu, Z., Dai, H. and Moghimi, S. M.* (2008) Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 45: 3797–3803. 3. Hamad, I., Hunter, A. C., Szebeni, J. and Moghimi, S. M.* (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46: 225–232. 4. Moghimi, S. M.* and Moghimi, M. (2008) Enhanced lymph node retention of subcutaneously injected IgG-PEG-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochim. Biophys. Acta-Biomembranes 1778: 51–55. 5. Mukhopadhyay, R., Al-Hanbali, O., Pillai, S., Hemmersam, A. G., Meyer, R. L., Hunter, A. C., Rutt, K. J., Besenbacher, F., Moghimi, S. M. and Kingshott, P.* (2007) Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. J. Am. Chem. Soc. 129: 13390–13391. 6. Moghimi, S. M.*, Hamad, I., Andresen, T. L., Jørgensen, K. and Szebeni, J. (2006) Methylation of the phosphate oxygen moiety of phospholipid-mthoxypoly(ethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20: 2591–2593 (doi: 10.1096/fj.06-6186fje, electronic pages E2057–E2067). 7. Moghimi, S. M.* (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144. 8. Moghimi, S. M.*, Symonds, P., Murray, J. C., Hunter, A. C., Debska, G. and Szewczyk, A. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. Mol. Ther. (Am. Soc. Gene Ther.) 11: 990–995. 9. Moghimi, S. M.*, Hunter, A. C. and Murray, J. C. (2005) Nanomedicine: current status and future prospects. FASEB J. 19: 311–330. 10. Moghimi, S. M.*, Hunter, A. C., Murray, J. C. and Szewczyk, A. (2004) Cellular distribution of nonionic micelles. Science 303: 626–627. 11. Moghimi, S. M.* and Szebeni, J. (2003) Stealth liposomes and nanoparticles: critical issues on protein-binding properties, activation of proteolytic blood cascades and intracellular fate. Prog. Lipid Res. 42: 463–478. 12. Moghimi, S. M.* (2002) Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta-Mol. Cell Res. 1590: 131–139. 13. Moghimi, S. M.*, Hunter, A. C. and Murray, J.C. (2001) Long circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53: 283–318.
Links: http://www.farma.ku.dk/index.php/Centre-for-Pharmaceutical-Nano/6363/0/
|
